You are here: Industry Insights > Alzheimer's

News List

Biogen urges Medicare to reverse proposed limits on coverage of Alzheimer's drug FirstWordPharma
February 11, 2022
Biogen is urging Medicare to broadly reimburse its Alzheimer's drug Aduhelnm, in response to a proposal by the US Centers for Medicaid and Medicare Services (CMS) to sharply limit coverage of new drugs for the disease...
Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland prnasia
November 11, 2021
Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon)...
Some Diabetes Meds Might Also Lower Alzheimer's Risk drugs
August 13, 2021
Older adults who take certain diabetes drugs may see a slower decline in their memory and thinking skills, a new study suggests.
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's prnasia
August 05, 2021
Alterity Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375.
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease prnasia
August 02, 2021
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated.
KeifeRx Receives FDA Acceptance of Investigational New Drug for Alzheimer's Disease americanpharmaceuticalreview
August 02, 2021
KeifeRx, LLC announced that the company received an acceptance of its Investigational New Drug (IND) application from the US FDA to launch a Phase 3 trial named NILEAD for Nilotinib BE.
Deaths From Alzheimer's Far More Common in Rural America drugs
August 02, 2021
Death rates from Alzheimer's disease are particularly high in the rural United States, a preliminary study finds, highlighting a need for health care resources in traditionally under-served areas.
COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms firstwordpharma
July 30, 2021
Much has been learned about SARS-CoV-2, the virus that causes the novel coronavirus, since the beginning of the COVID-19 pandemic. However, questions remain about the long-term impact of the virus on our bodies and brains.
New Prescribing Instructions Tighten Use of Controversial Alzheimer's Drug drugs
July 09, 2021
The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer's medication Aduhelm that will likely limit its use.
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's prnasia
July 02, 2021
Alterity Therapeutics has announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).